Microbiome Therapeutics for Clostridioides difficile Infection - 28/10/25

Doi : 10.1016/j.idc.2025.07.007

Christine W. Lucky, MD, MPH ^a, Rachel L. Medernach, MD, MSCI ^a,^⁎ , Brendan J. Kelly, MD, MSCE ^b,^c,^d, Jennie H. Kwon, DO, MSCI ^e, Michael H. Woodworth, MD, MSc ^f
^a Division of Infectious Diseases, Department of Medicine, Rush University, 600 South Paulina Street, Armour Academic Center, Suite 143, Chicago, IL 60612, USA
^b Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, 731 Blockey Hall, Philadelphia, PA 19104, USA
^c Division of Infectious Diseases, Department of Epidemiology, University of Pennsylvania, Philadelphia, PA, USA
^d Division of Infectious Diseases, Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA
^e Medicine, Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, 4523 Clayton Avenue, MSC 8051-0043-15, St Louis, MO 63110, USA
^f Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, 1760 Haygood Drive NE, Atlanta, GA 30322, USA

^∗Corresponding author. Division of Infectious Diseases, Rush University, 600 South Paulina Street, Armour Academic Center, Suite 143, Chicago, IL 60612.Division of Infectious DiseasesRush University600 South Paulina StreetArmour Academic CenterSuite 143ChicagoIL60612

Résumé

Microbiota-based therapies are used increasingly for the treatment and prevention of Clostridioides difficile infection (CDI), particularly in cases of recurrent CDI (rCDI). This review discusses the different types of microbiota-based therapies, including fecal microbiota transplant, fecal microbiota products, and live biotherapeutic products. The authors present efficacy data regarding clinical use in rCDI and highlight the unique aspects of each product.

Le texte complet de cet article est disponible en PDF.

Keywords : Clostridioides difficile infection, Fecal microbiota transplant, Fecal microbiota products, Live biotherapeutic products, Recurrent C difficile, Microbiome